Sysmex Europe Launches Automated Blood Testing Platform for Alzheimer’s Disease
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
The system uses routine blood draws to provide results in 17 minutes, offering an alternative to invasive diagnostic methods.
A simplified test of HDL's ability to remove cholesterol was associated with high-risk coronary plaques in a study of 61 patients.
The new recommendations add blood-based testing and multi-target stool testing as options for average-risk adults starting at age 45.
The updated test includes additional DPYD variants recommended by the Association for Molecular Pathology to help identify patients who may be at risk for severe chemotherapy side effects.
The facility will support the clinical validation of diagnostic kits that provide results via a mobile app without the need for laboratory processing.
AOA Dx presented data at AACR 2026 supporting its AKRIVIS GD Test System, a multi-omic, blood-based assay for early ovarian cancer detection in symptomatic women, reporting an AUC of 0.92 in clinical controls.
The Elecsys NfL test measures a protein associated with nerve cell injury to monitor disease activity in patients with relapsing remitting multiple sclerosis.
The new kit uses Tasso+ collection technology and certified laboratory analysis to monitor 17 health markers, including blood sugar and lipid levels.
Biomarkers in midlife adults without dementia may be linked to the earliest signs of waning cognition, researchers found.
As diabetes testing evolves, labs are seeing growing interest in earlier screening, additional biomarkers, and tools that can support more preventive care.
Insight Molecular Diagnostics has completed clinical validation and received ISO 13485 certification for its GraftAssureDx kidney transplant rejection test kit, moving toward FDA submission, according to the company.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.